Benzinga | Jul 14, 2021 06:04AM EDT

Baader Helvea Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $21

Baader Helvea initiates coverage on ATAI Life Sciences (NASDAQ:ATAI) with a Buy rating and announces Price Target of $21.